Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
57
BBC Quote, Financials, Valuation and Earnings
Last price:
$21.85
Seasonality move
:
-4.73%
Day range:
$21.73 - $22.04
52-week range:
$13.42 - $31.65
Dividend yield:
1.1%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
10.7K
Avg. volume:
41.2K
1-year change:
-24.81%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$21.88 | -- | -- | -- | $0.24 | 1.1% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$62.66 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$65.62 | -- | -- | -- | $0.13 | 0.25% | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
$18.25 | -- | -- | -- | $0.12 | 7.89% | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
$39.48 | -- | -- | -- | $0.00 | 0.09% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$88.12 | -- | -- | -- | $0.01 | 0.04% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.073 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 0.688 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.915 | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | 0.323 | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | 1.111 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.018 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
Virtus LifeSci Biotech Clinical Trials ETF vs. Competitors
-
Which has Higher Returns BBC or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is BBC or BBP More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.982, which suggesting that the stock is 1.842% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.58%.
-
Which is a Better Dividend Stock BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.1%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns BBC or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is BBC or PBE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.982, which suggesting that the stock is 1.842% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.810, suggesting its less volatile than the S&P 500 by 19.007%.
-
Which is a Better Dividend Stock BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.1%. Invesco Biotechnology & Genome ETF offers a yield of 0.25% to investors and pays a quarterly dividend of $0.13 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns BBC or PFFR?
InfraCap REIT Preferred ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat InfraCap REIT Preferred ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- -
What do Analysts Say About BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand InfraCap REIT Preferred ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than InfraCap REIT Preferred ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than InfraCap REIT Preferred ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PFFRInfraCap REIT Preferred ETF0 0 0 -
Is BBC or PFFR More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.982, which suggesting that the stock is 1.842% less volatile than S&P 500. In comparison InfraCap REIT Preferred ETF has a beta of 0.693, suggesting its less volatile than the S&P 500 by 30.701%.
-
Which is a Better Dividend Stock BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.1%. InfraCap REIT Preferred ETF offers a yield of 7.89% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. InfraCap REIT Preferred ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than InfraCap REIT Preferred ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than InfraCap REIT Preferred ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while InfraCap REIT Preferred ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for InfraCap REIT Preferred ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- --
-
Which has Higher Returns BBC or PSCH?
Invesco S&P SmallCap Health Care ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Invesco S&P SmallCap Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- -
What do Analysts Say About BBC or PSCH?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P SmallCap Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Invesco S&P SmallCap Health Care ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Invesco S&P SmallCap Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PSCHInvesco S&P SmallCap Health Care ETF0 0 0 -
Is BBC or PSCH More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.982, which suggesting that the stock is 1.842% less volatile than S&P 500. In comparison Invesco S&P SmallCap Health Care ETF has a beta of 0.958, suggesting its less volatile than the S&P 500 by 4.237%.
-
Which is a Better Dividend Stock BBC or PSCH?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.1%. Invesco S&P SmallCap Health Care ETF offers a yield of 0.09% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Invesco S&P SmallCap Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PSCH?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Invesco S&P SmallCap Health Care ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Invesco S&P SmallCap Health Care ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Invesco S&P SmallCap Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Invesco S&P SmallCap Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- --
-
Which has Higher Returns BBC or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About BBC or XBI?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is BBC or XBI More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.982, which suggesting that the stock is 1.842% less volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.345%.
-
Which is a Better Dividend Stock BBC or XBI?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.1%. SPDR S&P Biotech ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.01 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XBI?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
80
SOC alert for Jul 18
Sable Offshore [SOC] is up 11.47% over the past day.
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 6.14% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.93% over the past day.
